MarketOptimizer.org adds new report “Cangrelor (Acute Coronary Syndrome) – Forecast and Market Analysis to 2023” to its store. Overview of ACS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
New PharmaPoint Drug Evaluation report, “Cangrelor (Acute Coronary Syndrome) – Forecast and Market Analysis to 2023”. The current ACS market – primarily comprised of antithrombotics, antihypertensives, and statins – is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of action and target orphan biochemical pathways. The ACS market will be driven by an aging population with a preponderance of lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disorders such as diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the Acute Coronary Syndrome market, both medically and financially.
The Medicines Company’s co-promotion of Brilinta began in the US in 2012. AstraZeneca’s role in marketing cangrelor, if and when it is approved, is unclear. According to the 2003 acquisition and the 2012 agreement, The Medicines Company will not have marketing rights to cangrelor in Japan. Researcher assumes, for this forecast, that AstraZeneca will retain marketing privileges for cangrelor in Japan, where Researcher expects cangrelor will launch in 2018.
Cangrelor is a P2Y12 inhibitor under investigation as an antiplatelet drug for intravenous application. Some P2Y12 inhibitors are used clinically as effective inhibitors of adenosine diphosphate-mediated platelet activation and aggregation. Unlike clopidogrel (Plavix), which is a prodrug, cangrelor is an active drug not requiring metabolic conversion. Poor interim results led to the abandonment of the two CHAMPION clinical trials in mid-2009. The BRIDGE study, for short term use prior to surgery, continues. The CHAMPION PHOENIX trial was a randomized study of over 11,000 patients published in 2013. It found usefulness of cangrelor in patients getting cardiac stents. Compared with clopidogrel given around the time of stenting, intravenous ADP-receptor blockade with cangrelor significantly reduced the rate of stent thrombosis and myocardial infarction. Reviewers have questioned the methodology of the trial.
Cangrelor is a high-affinity, reversible inhibitor of P2Y12 receptors that causes almost complete inhibition of ADP-induced platelet aggregate. It is a modified ATP derivative stable to enzymatic degradation. It does not require metabolic conversion to an active metabolite. This allows cangrelor’s immediate effect after infusion, and the therapeutic effects can be maintained with continuous infusion. The pharmacokinetics of cangrelor has allowed it to rapidly achieve steady-state concentrations with a clearance of 50 L/h and a half-life of 2.6 to 3.3 minutes. Cessation of its administration is associated with rapid removal, and normal platelet function is restored within 1 hour
Overview of ACS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on Aricept including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for Aricept for the top seven countries from 2013 to 2023.
Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.
Reasons to Buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for ACS
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Aricept performance
- Obtain sales forecast for Aricept from 2013-2023 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)
Major Points in Table of Content
1 Table of Contents
2 Executive Summary
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.4 Quality of Life
5 Disease Management
5.1 Treatment Overview
6 Competitive Assessment
6.2 Strategic Competitor Assessment
7 Unmet Need and Opportunity
7.2 Therapies that Directly Treat Thrombogenic Atherosclerotic Plaques
7.2.1 Unmet Need
7.2.2 Gap Analysis
7.3 Therapies that Treat Fibrotic Myocardium and Associated Comorbidities
7.3.1 Unmet Need
7.3.2 Gap Analysis
7.4 LDL-C-Lowering Drugs for Statin-Intolerant, Refractory, or Non-Compliant Patients
7.4.1 Unmet Need
7.4.2 Gap Analysis
7.5 Antidotes for New Oral Anticoagulants (NOACs)
7.5.1 Unmet Need
7.5.2 Gap Analysis
7.6 Blood-Thinning Agents with Significantly Reduced Bleeding Risks
7.6.1 Unmet Need
7.6.2 Gap Analysis
8 Pipeline Assessment
8.2 Clinical Trials by Phase and Trial Status
8.3 Promising Drugs in Clinical Development
9.4 Dosing and Formulation
9.5 Potential Clinical Positioning
9.6 Potential Commercial Positioning
9.7 Pricing and Reimbursement
9.8 SWOT Analysis
MarketOptimizer.org is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
Explore more reports on Acute Coronary Syndrome:
Acute Coronary Syndrome – US Drug Forecast and Market Analysis to 2023 :
Of the 7MM forecast for acute coronary syndrome, the US market dominates the other six countries in sales for every class and brand of drug, by a very large margin. The statin share can predominantly be attributed to sales volume as most statins, with the exception of Crestor, are available as inexpensive generics. Contrarily, the large market share from the ARBs is due to the relatively high cost of therapy and the presence of branded options still on the market.
Acute Coronary Syndrome – Japan Drug Forecast and Market Analysis to 2023 :
By the end of the forecast period, GlobalData projects that the Japanese market will overtake the Italian market in size, becoming the fourth largest market behind the US, Germany, and the UK. The Japanese antiplatelet market in 2013 was the smallest of all 7MM due to the pending product launches of Brilinta and Effient.
SOURCE Life Science Industry Research